No Data
No Data
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan
Merrimack Pharmaceuticals (MACK) said late Wednesday it has received a $225 million milestone payment from Ipsen and called for a special stockholder meeting on May 10 to approve a plan of dissolution
Merrimack Receives $225M Milestone Payment From Ipsen
Merrimack Receives $225 Million Milestone Payment From Ipsen
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it has received a $225 million payment which was due from Ipsen, S.A. as a result of its receipt of approval from the U.S. Food and Drug Administration, or FDA, to market ONIVYDE as a first-line treatment of metastatic adenocarcinoma on the pancreas.
Merrimack Pharmaceuticals Proposes Liquidation Plan
Express News | Merrimack FY23 EPS $(0.08) Per Basic Share
Merrimack Reports Full Year 2023 Financial Results
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December 31, 2023.
No Data
Jaguar8 : I love the milestone payment but dissolution weighed it down
TrytosaveabitOP Jaguar8: Yup! I believe you’re correct